Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
11 |
Material Type: Artigo
|
225 Variable distribution of TRAIL Receptor 1 in primary human tumor and normal tissuesHalpern, W. ; Lincoln, C. ; Sharifi, A. ; Roach, C. ; Askaa, J. ; Klein-Szanto, A. ; Cohen, R.European journal of cancer supplements, 2004-09, Vol.2 (8), p.69-69 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
|
12 |
Material Type: Artigo
|
232 Unique molecular recognition of CD20 by the type II CD20 antibody GA101Niederfellner, G.J ; Lammens, A ; Georges, G.J ; Schwaiger, M ; Franke, A ; Wiechmann, K ; Moessner, E ; Umana, P ; Hopfner, K.P ; Klein, CEuropean journal of cancer supplements, 2010, Vol.8 (7), p.75-76 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
|
13 |
Material Type: Artigo
|
26 Overcoming the limitations of lung cancer radiotherapy by targeting the CD73/adenosine immune checkpointDe Leve, S ; Meyer, A ; Wirsdörfer, F ; Klein, D ; Stuschke, M ; Jendrossek, VESMO open, 2018-07, Vol.3 (Suppl 2), p.A12-A12 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
|
14 |
Material Type: Artigo
|
283 The trifunctional antibody catumaxomab: mode of actionSeimetz, D ; Linke, R ; Atz, J ; Essing, M ; Klein, AEuropean journal of cancer supplements, 2010, Vol.8 (5), p.74-74 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
|
15 |
Material Type: Artigo
|
30 Neuroblastoma and melanoma metastasis: regulation by the tumour microenvironmentWitz, I ; Izraely, S ; Klein, A ; Edry-Botzer, L ; Maman, S ; Sagi-Assif, O ; Meshel, T ; Hoon, DEuropean journal of cancer supplements, 2010, Vol.8 (5), p.8-8 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
|
16 |
Material Type: Artigo
|
30-year prospective longitudinal study of ADHDKlein, R.G ; Mannuzza, SEuropean psychiatry, 2008-04, Vol.23, p.S382-S382 [Periódico revisado por pares]Elsevier Masson SASTexto completo disponível |
|
17 |
Material Type: Artigo
|
3603 Management of unresectable metastatic colorectal cancer (MRCC) in the real world with successive regimens with targeted therapies (Bevacizumab and cetuximab): the experience of the OMIT Bretagne Pays de LoireMetges, J.P ; Gamelin, E ; Faroux, R ; Klein, V ; Ganem, G ; Douillard, J.Y ; Stampfli, C ; Corbinais, S ; Riche, C ; Grude, FEuropean journal of cancer supplements, 2009, Vol.7 (2), p.209-209 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
|
18 |
Material Type: Artigo
|
408 A phase II study of erlotinib in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (PHL-002e/NCIC CTG IND.157)Winquist, E. ; Soulieres, D. ; Chen, E. ; Tsao, M. ; Klein, M. ; Pond, G. ; Dancey, J. ; Eisenhauer, E. ; Siu, L.L.European journal of cancer supplements, 2004-09, Vol.2 (8), p.122-122 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
|
19 |
Material Type: Artigo
|
409 POSTER Identification of novel candidate genes for targeted therapy of primary cutaneous T-cell lymphomasRanki, A. ; Hahtola, S. ; Tuomela, S. ; Burghart, E. ; Elo, L. ; Karenko, L. ; Krohn, K. ; Lahesmaa, R. ; Monni, O. ; Klein, C.European journal of cancer supplements, 2006-11, Vol.4 (12), p.126-126 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
|
20 |
Material Type: Artigo
|
414 Correlation of mutations in EGFR with clinical outcomes in NSCLC patients treated with erlotinibEberhard, D. ; Amler, L. ; Goddard, A. ; Ince, W. ; Januario, T. ; Hillan, K. ; Ostland, M. ; Ramies, D. ; Seshagiri, S. ; Klein, P.European journal of cancer supplements, 2004-09, Vol.2 (8), p.124-124 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |